Latrepirdine dihydrochloride is under clinical development by Bigespas and currently in Phase III for Dementia Associated With Alzheimer’s Disease. According to GlobalData, Phase III drugs for Dementia Associated With Alzheimer’s Disease have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Latrepirdine dihydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Latrepirdine dihydrochloride overview
Latrepirdine dihydrochloride is under development for the treatment of Alzheimer type dementia. The drug candidate is administered through oral route. It acts by targeting amyloid beta protein.
Bigespas overview
Bigespas carries out the business of supplying pharmaceutical products. The company is headquartered in London, Greater London, the UK.
For a complete picture of Latrepirdine dihydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
